Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

Benzinga · 2d ago
Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.